g****e
发帖数: 1426 | 1 From my blog:
http://www.mitbbs.com/pc/pccon_12673_259271.html
Current price: $13.75
Resistence levels: $15, $20
Target price: $28 if successful REMS revision to include retail distribution
from FDA in mid April
In JPM conference tomorrow, CEO Leland Wilson most likely will provide
updates about steady progress on script writing and mail order.
Other near term catalysts:
1. Q4 2012 Qsymia sale;
2. FDA decision on REMS revision to include retail distribution in Mid April;
3. Appeal the decision from the CHMP, A new decision in expected in second Q
of 2013;
4. Partnership announcement if item 2 successful
Personally I believe highly likely we will have positive outcomes on items 1
, 2 and 4. Long and strong on VVUS!
YMYD, do your own DD before investing. |
C**X
发帖数: 25 | |
c*********o
发帖数: 8367 | 3 this one is also crazy...LOL
distribution
【在 g****e 的大作中提到】
: From my blog:
: http://www.mitbbs.com/pc/pccon_12673_259271.html
: Current price: $13.75
: Resistence levels: $15, $20
: Target price: $28 if successful REMS revision to include retail distribution
: from FDA in mid April
: In JPM conference tomorrow, CEO Leland Wilson most likely will provide
: updates about steady progress on script writing and mail order.
: Other near term catalysts:
: 1. Q4 2012 Qsymia sale;
|
b******n
发帖数: 104 | 4 请问新药正式发向市场开售，对药股是利好吗？还是要看市场反馈才能决定股价升降？
VVUS和AMRN的药是不是快要上市了？多谢回答 |
g****e
发帖数: 1426 | 5 Projection could drive share up, but Sale numbers ultimately are the key!
BTW, VVUS Qsymia has been available since last September. |
b******n
发帖数: 104 | |
C**X
发帖数: 25 | |
g****e
发帖数: 1426 | |
m*****i
发帖数: 4342 | 9 One of my friend went to JP Morgan global HC conference at Hilton in San
Francisco. I gave him the name of couple of good chinese restaurant in the
area.
【在 g****e 的大作中提到】
: Nice run today!!
|
g****e
发帖数: 1426 | 10 How it relates to VVUS? |
g****e
发帖数: 1426 | 11 Since the last call, it went over $15.5. Then went down..
Now @12.43. It seems 11.90 is a bottom and will have lots of catalyst events
to move it up.
Next catalyst before ER:
Feb 13, 2013
Vivus Inc. at Leerink Swann Global Healthcare Conference -
12:00PM EST
Overall, I think VVUS is very bullish in 2013. Prescription scripts have
been steady up and the market is surly huge. Furthermore, large shareholders
are angry about the stock performance and threat to put the company for
sale. Remember it had dilution over $20 in the latest offering. It will be
my main stock to trade this year, so far so good.
Good luck to you all! |
k********n
发帖数: 18523 | 12 ok
Monday i buy 100 call 15 March |
g****e
发帖数: 1426 | 13 Watch this and buy any dip. It will go up big before the 02/13 conference
(If the global mark not bad). |
D******e
发帖数: 11265 | |
